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More than 35 million people remain infected with HIV-1. Upon antiretroviral therapy 
cessation, HIV-1-positive individuals systematically fail to achieve sustained virological 
remission, revealing the presence of a reservoir. This reservoir takes into account anatomical 
sanctuaries where HIV-1 continues to replicate, and latently infected cells also known as 
the latent reservoir (LR). A better understanding of the nature and features of the LR and 
its quantification are crucial to evaluate the efficiency of therapeutic strategies aiming at 
purging HIV-1. Culture- and PCR-based assays have already been implemented to measure 
the LR, and new assays are continuously being developed. In this review, we will discuss 
these methods highlighting the difficulties to accurately measure the LR, one main obstacle 
in curing HIV-1.
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30 years ago, it was unthinkable for HIV-1-positive individuals to have a life expectancy above 
a decade [1]. With the development of antiretroviral therapy (ART), the mortality and morbid-
ity associated with HIV-1 infection have been successfully reduced although >35 million people 
remain infected with HIV-1 [2,3]. ART effectively reduces plasma viral loads to undetectable levels 
by targeting specific replication steps of HIV-1 thus allowing treated patients to live longer despite a 
lifelong treatment, high costs and severe adverse effects [4]. Indeed, upon ART interruption viremia 
rebounds typically within a few weeks suggesting the presence and release of virus from a stable 
reservoir [2]. This reservoir is established early during infection, providing the basis for treating 
HIV-1-positive individuals as soon as possible during acute infection [5,6]. To date, two main sources, 
which are not mutually exclusive, are thought to contribute to the viral reservoir: the persistence 
of productive infected cells in lymphoid tissues and anatomical sites that are inaccessible to ART; 
and the persistence of latently infected cells that are able to produce viral particles upon stimula-
tion also known as the latent reservoir (LR), and which is the main focus of this review [7–9]. The 
existence of this HIV-1 reservoir is considered to be the major handicap to HIV-1 eradication and 
an increasing number of studies focus on finding new strategies to eliminate it [2,10–11].
HIV-1 primarily infects activated CD4+ T cells and macrophages. Macrophages can contribute to 
HIV-1 persistence mainly due to their presence in different anatomical sanctuaries such as the CNS 
and the gut [3,12]. Tissue-resident macrophages can live up to several months and can thus contribute 
to the maintenance of viral production, but their impact on the HIV-1 reservoir is still poorly under-
stood [3]. Additional cell populations may affect the reservoir but their exact role remains to be elu-
cidated [4]. During HIV-1 infection, the majority of activated CD4+ T cells usually die shortly after 
For reprint orders, please contact: reprints@futuremedicine.com
Future Virol. (2016) 11(12)786
REVIEW Hodel, Patxot, Snäkä & Ciuffi
future science group
infection because of virus-mediated cytotoxicity 
or immune-mediated killing. However, some of 
these cells will return to a resting memory state 
and do not release viral particles, giving rise to 
latently infected cells [2,3]. As they do not express 
viral proteins, these latently infected cells are no 
longer targeted by the immune system, and ART 
is not effective. These resting memory CD4+ 
T cells have been identified as the main cellular 
reservoir harboring latent provirus [2–3,7,9]. The 
persistence of this LR is directly linked to key 
features of both the retrovirus and the resting 
memory of CD4+ T cells, which are the stable 
viral genome insertion in the host genome and 
the long half-life of infected cells [4,11,13].
Understanding the LR is key to design new 
approaches aiming at curing HIV-1. Cells har-
boring latent HIV-1 represent only 10–100 in 
106 of resting CD4+ T cells; however, reactiva-
tion of these cells in HIV-1-positive individuals 
off ART is sufficient to viral rebound [11,13–14]. 
Some of the most attractive strategies, such 
as the ‘shock and kill’, aim at reactivating the 
latently infected CD4+ T cells using latency-
reversing agents (LRA) to induce expression of 
viral proteins, which triggers the elimination of 
the infected cells by the immune system or by 
virus-induced cytotoxicity [2,3]. Although attrac-
tive, no LRA alone seemed potent enough to 
induce expression from all latently infected cells, 
suggesting that, as for drug treatment, combina-
tion of multiple LRA might represent an alterna-
tive strategy [14]. Thus, a better characterization 
of the LR and the multiple mechanisms leading 
to latency is required to better understand the 
ins and outs of the inducible LR.
The accurate quantification of the LR in HIV-
1-infected individuals is essential for evaluating 
HIV-1 eradication strategies and for deciding on 
whether and when ART interruption is legiti-
mate [11]. Quantifying the true size of the LR is 
extremely challenging due to characteristics of 
both the viral genome and the latently infected 
cell. Indeed, as illustrated in Figure 1, many inte-
grated proviral sequences are hypermutated, and 
thus defective and unable to produce replication-
competent viral particles. A study by Ho et al. 
showed that about 88% of cells carrying HIV-1 
DNA contained a large deletion rendering 
them defective [11]. Thus, only about 12% of 
infected cells carry a replication-competent viral 
genome and would represent the bona fide LR. 
Furthermore, in vitro, only a fraction of these 
cells was effectively inducible using one round of 
CD4+ T-cell stimulation [11,13]. Thus, these two 
features, replication-competent versus defective 
virus, and inducible versus noninducible virus, 
represent significant challenges for the develop-
ment of reliable assays measuring the LR. The 
current review aims at providing an overview 
of assays currently used to evaluate the size of 
the ‘true’ LR as well as discussing their clinical 
relevance.
Culture-based assays to measure the LR
Culture-based assays (Figure 2) aim at measur-
ing the LR by assessing the number of cells 
that carry replication-competent viruses. These 
assays use pharmacological or immunological 
agents to reactivate the LR and induce replica-
tion-competent HIV-1 in resting CD4+ T cells. 
Additional CD4+ T cells are added to the pri-
mary cell culture to further promote HIV-1 
replication and thereby allow HIV-1 amplifica-
tion. These assays measure the frequency of cells 
producing viral particles, able to replicate and 
propagate and offer great potential to measure 
the LR. However, it is essential to note that these 
assays rely on the ability of cells to be stimu-
lated and thus to induce the LR. To date, T-cell 
receptor-mediated stimulation is considered to 
be the most powerful stimuli to activate CD4+ 
T cells; however, they are not able to induce viral 
expression from all latently infected cells [11].
●● Quantitative viral outgrowth assay: ‘the 
gold standard’
Quantitative viral outgrowth assay (QVOA) 
was the f irst assay developed that permit-
ted identif ication and measurement of the 
LR, and is currently considered as the gold 
standard [2,11].
QVOA measures the frequency of rest-
ing CD4+ T cells able to produce replication 
competent and therefore infectious virus 
upon stimulation. Resting CD4+ T cells are 
isolated from peripheral blood mononuclear 
cells (PBMCs) by density gradient centrifuga-
tion and further purified by negative selection. 
These cells are considered resting since they do 
not express classical activation markers such as 
CD69, CD25 or HLA-DR and in most cases 
do not produce virus without stimulation [2,13]. 
Fivefold dilutions are performed to distribute 
the cells into wells, such that the input num-
ber of patient cells ranges from 1,000,000 
to 320 cells per well. To reverse latency, 
T-cell activation is carried out using mitogen 
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phytohemagglutinin (PHA) and tenfold excess 
of γ-irradiated PBMCs from healthy donors. 
After 1 day of stimulation, CD4+ lymphoblasts 
from healthy donors are added at two differ-
ent time points to allow HIV-1 replication and 
propagation. On day 14, supernatant of each 
well is analyzed by HIV-1 p24 antigen ELISA 
to identify wells positive for viral outgrowth. 
Based on this, the frequency of cells releasing 
virus can be determined using maximum like-
lihood method. This assay first indicated an 
average of one latently infected cell (able to pro-
duce replication-competent virus) in 1 million 
resting CD4+ T cells, thereby defining the first 
estimate of the LR size.
Although HIV-1 induction by PHA activa-
tion was thought to be uniform and maximal, 
studies by Ho et al. [11] followed by Cillo et al. [15] 
showed that one single round of activation was 
not sufficient to reactivate all intact proviruses. 
Indeed, 98.5% of the viral reservoir was not 
induced upon activation, which indicates that 
QVOA largely underestimates the size of the 
LR. Although the majority of these noninduced 
proviruses after one round of stimulation are 
defective, it has been shown that a significant 
proportion (11.7%) of noninduced proviruses 
has intact genomes and is potentially replication 
competent [13,15]. Additional rounds of stimula-
tion could induce expression of infectious virus 
from additional latently infected cells, suggest-
ing that the true LR size might rather be around 
60–70 latently infected cells per million of rest-
ing CD4+ T cells. Thus, QVOA can only give a 
definitive minimal estimate of the frequency of 
latently infected CD4+ T cells and relies on the 
ability of compounds or stimuli to efficiently 
induce viral expression from the LR [2,13,15].
In addition to underestimating the LR size, 
QVOA presents multiple drawbacks. It is time-
consuming, labor-intensive and expensive since 
it requires multiple weeks of cell culture with 
multiple media changes in a Biosafety Level 3 
(BSL3) laboratory, and is therefore not suitable 
for large-scale studies. This assay also has a lim-
ited dynamic range and requires large sample 
volumes (120–180 ml) from HIV-1-positive 
individuals and healthy blood donors. Despite 
these limitations, it is considered as a gold 
standard since positive viral outgrowth is a 
direct proof of the persistence of the LR and 
thereby calls for caution for ART interruption. 
Attempts to improve this assay are still being 
pursued.
●● MOLT4/CCR5 viral outgrowth assay: a 
slight improvement of the gold standard
The limitations and drawbacks of QVOA are 
called for improvements and development of new 
assays to measure the LR. MOLT4/CCR5 viral 
outgrowth assay (VOA) allows a faster measure-
ment of the number of latently infected CD4+ 
T cells [13]. To avoid the need of high amounts of 
donor cells, a MOLT4/CCR5 T-cell line is used 
to propagate the virus. These cells express both 
CXCR4 and CCR5 co-receptors, and are highly 
permissive to HIV-1 replication [2,13]. In addi-
tion, these MOLT4/CCR5 cells are added only 
once after activation. To replace the ELISA used 
in QVOA, a more sensitive reverse transcription 
(RT)-PCR assay is used only after 7 days to 
quantify viral RNA copies in the supernatant 
of each well, thereby reducing the time needed 
to perform the assay. The frequency of latent 
cells measured by MOLT4/CCR5 VOA corre-
lates with QVOA and no significant difference 
was observed between the two methods [2,13].
MOLT4/CCR5 VOA offers great potential 
according to Laird et al. to replace the stand-
ard QVOA method, since it is more rapid and 
sensitive, cost-effective, less cell-consuming, less 
labor-intensive and therefore more suitable for 
large-scale clinical trials [13]. However, it is still 
quite demanding and, as for QVOA, the true 
size of the LR is likely to be underestimated [13].
●● Murine VOA: the first in vivo measurement 
of the LR
To avoid the underestimation of the reservoir, 
Pate et al. proposed a novel VOA assay [16]. 
Instead of cell culture, it uses an immunocom-
promised murine model (NOD.Cg-PrkcscidIl-
2rgtm1Wjl/SzJ (NSG), Jackson Laboratories, Bar 
Harbor, ME, USA) in which purified PBMCs 
or resting CD4+ T cells from an HIV-1-positive 
individual are injected intraperitoneally to trans-
fer the LR into the mouse. CD8+ T cells are 
then depleted using anti-human CD8 antibody 
to minimize the potential antiviral response and 
allow maximal viral amplification. T cells are 
then activated with anti-human CD3 antibody 
to induce viral replication from patient-derived 
latently infected cells. To quantify viral ampli-
fication in mice blood samples, HIV-1 RNA 
plasma levels are measured by quantitative RT-
PCR. Detection of replication-competent HIV-1 
occurred on average at day 20 with a median 
peak viral load of 4.6 × 103 copies/ml at an 
average of 25 days [16].
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Pate et al. established a new in vivo model to 
detect residual virus, allowing prediction of viral 
rebound without endangering the patient [16]. 
The assay is relatively simple and although it 
is not quantitative, it is more sensitive than 
QVOA. However, murine VOA has some limita-
tions. The main drawbacks are the requirements 
of a BSL3 animal facility, animal handling and 
specialized technicians, which may not always be 
applicable for clinics. In addition, the sensitivity 
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Figure 1. Characterization of the latent reservoir (see facing page). Two major types of resting CD4+ T cells are shown, containing 
either intact or defective HIV-1. Defective HIV-1 contains large internal deletions, G→A hypermutations or other defects. In both cases, 
following a single round of T-cell activation, proviruses are either induced to produce virions that can infect other cells (induced, 
replication-competent HIV-1) or to produce defective virions unable to infect other cells (induced, replication noncompetent 
HIV-1). Proviruses that are not induced to produce virions following a single round of T-cell activation are termed noninduced 
HIV-1. The noninduced HIV-1 can still be induced after additional rounds of activation. On subsequent rounds of cellular activation, 
some noninduced proviruses can produce either competent or noncompetent virions. Culture-based assays detect only induced 
replication-competent HIV-1, while PCR-based assays detect all types of proviruses. The true latent reservoir includes only induced 
replication-competent HIV-1 and noninduced intact HIV-1.
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of the method is highly related to the quality 
of the xenograft, and the time needed for viral 
detection varies between patients. The current 
model only measures the reservoir in the periph-
eral blood, but the authors estimate that it will 
be applicable to other tissues. The study was 
conducted on a limited number of patients and 
further investigation is required to determine 
whether murine VOA is really more sensitive 
than QVOA and whether this method will be 
suited for quantitation of the reservoir and for 
its future implementation in clinics.
PCR-based assays to measure the LR
PCR-based assays (Figure 2) are commonly used 
to quantify total HIV-1 provirus, as they usually 
require minimal amounts of specialized equip-
ment. Furthermore, PCR can detect very small 
amounts of DNA/RNA, which is crucial due to 
the low copy numbers of HIV-1 in long-term 
ART-treated patients.
●● Quantitative PCR: the silver standard
Nowadays, PCR-based assays are widely used to 
measure the LR size, quantitative PCR (qPCR) 
for proviral DNA being the most common one [2]. 
CD4+ T cells are first purified from peripheral 
blood. Afterward, DNA is extracted and amplified 
by qPCR using HIV-1-specific primers as well as a 
fluorescent probe. Primers and probe for an endog-
enous housekeeping gene are used as well to assess 
the equivalent number of cell copy. qPCR allows 
quantification of HIV-1-specific PCR products 
by following cycle by cycle the appearance and 
the accumulation of fluorescence released during 
amplification, which is directly proportional to 
the amount of amplified HIV-1 DNA [18,19]. The 
assay gives, therefore, a relative quantification of 
HIV-1 DNA from a standard curve, and estimates 
the amount of HIV-1 DNA to be at an average of 
1000 copies per million cells. This frequency is 
at least two to three logs higher than measured 
by QVOA [2,20]. In fact, infected cells carry both 
intact and defective HIV-1 sequences, making 
this assay overestimating the LR size. Despite 
this overestimation, qPCR is less labor-intensive 
and faster than QVOA. Moreover, it does not 
require any extended culture time in BSL3 labo-
ratory [2]. However, PCR efficiency can be biased 
due to viral sequence variability caused by muta-
tions affecting primer binding, and to variable 
abundance of viral DNA between patients [19]. In 
summary, qPCR has been shown to be an effec-
tive surrogate to follow LR; and as HIV-1 DNA 
measured by qPCR is correlated to integrated 
HIV-1 DNA and to viral rebound in patients on 
suppressive ART, it can be used as a marker in cure 
research and patient monitoring to predict remis-
sion of HIV-1 [21,22]. Therefore, although DNA 
measurements of HIV-1 are likely to overestimate 
the LR, they are currently the best way to safely 
monitor the reservoir in clinical settings.
●● Droplet digital PCR or the digital 
revolution
Droplet digital PCR (ddPCR) is an emerging 
technology enabling high precision and repro-
ducibility at low DNA copy number [2,18–19,23]. 
ddPCR was initially developed to reduce noise 
observed in qPCR and to better detect low 
amounts of HIV-1 nucleic acids in patient sam-
ples. Following DNA extraction, ddPCR sys-
tems separate the sample into compartments, or 
so-called drops, by emulsification of the aqueous 
PCR reaction mixture in thermostable oil. Thus, 
only few molecules are present in each PCR par-
tition so that rare targeted viral DNA will stand 
out after PCR amplification reactions. Poisson 
statistics are used to predict how much starting 
material was present before amplification [24]:
Copies/Droplet ln 1 Total droplets
Positive droplets( )[ ]=- -
Unlike qPCR, ddPCR is a highly precise and 
sensitive method that allows absolute quantifi-
cation of HIV-1 DNA. ddPCR can be achieved 
in 1 day and is well appropriate to measure the 
LR size. By increasing the number of replicates 
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Figure 2. Measurement of the latent reservoir by seven different assays (see facing page). From top to bottom: Culture-based assays, 
PCR-based assays and novel assays. For each assay, the methodology used to measure the latent reservoir is indicated proportionally 
to the time needed to obtain the results. Culture-based assays are very time-consuming compared with PCR-based assays, but neither 
offers an accurate estimation of the latent reservoir. Novel assays approach the ‘true’ size and are less time-consuming compared with 
culture-based assays. 
PBMC: Peripheral blood mononuclear cell; PHA: Phytohemagglutinin; PMA: Phorbol myristate acetate; qRT: Quantitative real-time 
reverse transcription PCR.
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we can decrease the LOD. However, the rate 
of false positives, whose source is still unclear, 
remains a real challenge in measuring the LR 
with ddPCR; and like qPCR, it overestimates 
the LR size [23]. Only few laboratories use 
ddPCR since the instrumentation is expensive 
and requires specific expertise. Nonetheless, 
by performing simultaneously multiple qPCR 
reactions, ddPCR is an elegant adaptation of the 
current qPCR assay [2,19].
The next-generation assays
We have described above two main categories 
of assays measuring LR that both face major 
drawbacks: culture-based assays underestimate 
the size of the reservoir while PCR-based assays 
tend to overestimate it. The ‘true’ size is defined 
to be in-between, and new methods are needed 
to approach reality. Recently, three assays have 
been proposed to offer an alternative to estimate 
the LR: the tat/rev-induced limiting dilution 
assay (TILDA), the inducible cell-associated 
RNA expression in dilution (iCARED) assay 
and single molecule arrays (Simoa™, Quanterix 
Corporation, Lexington, MA, USA) (Figure 2).
●● Should TILDA, iCARED & Simoa be 
considered as alternatives to the gold 
standard?
TILDA measures the frequency of total 
CD4+ T cells that produce viral tat/rev HIV-1 
msRNA upon maximal cell activation [25]. The 
production of these cell-associated viral tran-
scripts is used as a marker of the cell’s ability 
to produce replication-competent virus [11,25]. 
Isolated total CD4+ T cells are stimulated for 
12 h with phorbol myristate acetate/Ionomycin, 
a presumably stronger activator than PHA [25]. 
Cells, serially diluted 1:3 from 18,000 to 1000 
cells, and in 22–24 replicates, are then directly 
added to the one-step RT-PCR mix to perform 
the reverse transcription reaction and amplify 
tat/rev sequence. A fraction of the first PCR is 
then used to perform a nested qPCR with HIV-
1-specific primers and probe to quantify tat/rev 
transcripts. To calculate the frequency of cells 
containing inducible HIV-1, a maximum likeli-
hood method that takes into account the num-
ber of cell input as well as the number of positive 
detections is used. This assay was used to meas-
ure the LR size of ART-suppressed individuals 
and estimated a median of 24 out of 1 million 
latently infected CD4+ T cells producing rep-
lication-competent virus upon stimulation. By 
comparison, the frequency of latently infected 
cells measured by TILDA was 48-times larger 
than QVOA, and 6–27 lower than by qPCR on 
total viral DNA.
TILDA is highly attractive since it requires 
only 10 ml of blood, does not rely on cell culture 
nor on RNA extraction, and the result is obtained 
within 2 days. In addition, this first study shows 
that TILDA is highly sensitive, reproducible, has 
a wide dynamic range and is suitable for clinical 
trials. However, the authors report a potential 
limitation since, even though all cells that do 
produce virus give a positive signal, some cells 
might produce tat/rev even without viral pro-
duction. The resulting overestimation of the 
reservoir seems lower than DNA-based qPCR 
assays, and the frequency of latently infected 
cells is closer to the prediction by Ho et al. [11]. 
Further studies are needed to validate TILDA to 
all quasispecies, as tat/rev region is variable and 
may introduce biases in viral detection. However, 
TILDA appears as an appealing alternative to 
VOA- and PCR-based assays.
iCARED is also a promising method, based 
on measurement of viral RNA [17]. Similarly to 
QVOA, CD4+ T cells are purified and used in 
threefold serial dilutions from 1,500,000 to 686 
cells in six to eight replicates [17]. Cells are acti-
vated to induce viral particle production using 
anti-CD3/anti-CD28 monoclonal antibodies 
that mimic antigen presentation, and in pres-
ence of the HIV-1 integrase inhibitor raltegravir 
to block viral propagation. After 3-day culture, 
RNA (from both virion-containing supernatant 
and cells) is extracted using magnetic beads to 
enrich for HIV-1-specific RNA. Primers and 
probe targeting either the gag region or the tat/
rev region were used to quantify cell-free and/
Future Virol. (2016) 11(12)792
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or cell-associated viral RNA by RT-qPCR using 
ddPCR. The size of HIV-1 LR as measured 
by iCARED was estimated to be 51 latently 
infected cells per million of CD4+ T cells, which 
is about 7–13-times more than by QVOA and 
19-times lower than total viral DNA by ddPCR. 
iCARED correlated well with QVOA at day 7 
and with measurements of total viral DNA [17]. 
iCARED is easy to perform, fast and highly sen-
sitive. Moreover, it is less cell demanding and less 
expensive than QVOA, and allows testing large 
volumes of cells and culture supernatants [17]. 
Thus, iCARED appears as a simple and innova-
tive method to quantify the HIV-1 LR, which 
can be useful for clinical investigations.
In addition to nucleic acids, proteins are also 
considered as reliable biomarkers for disease pro-
gression. However, relevant biomarkers are often 
present in very low abundance and conventional 
immunoassays lack in sensitivity [26]. Similarly 
to TILDA and iCARED, Simoa digital ELISA 
from Quanterix Corporation represents a novel 
promising assay for ultrasensitive detection of 
proteins at femtogram per milliliter levels [26–28]. 
This represents a >1:200-fold sensitivity improve-
ment compared with classical ELISA [26]. Simoa 
technology uses standard paramagnetic beads that 
are coupled with antibodies designed to bind the 
protein of interest in the sample. At low-protein 
abundance, each bead will only bind to one target 
protein or none. A biotin-labeled detection anti-
body is added into the reaction with its substrate 
streptavidin-β-galactosidase. The beads are then 
loaded onto microarrays that consists of >200,000 
femtoliter-sized wells. A single target molecule 
generates enough fluorescence to be detected by a 
camera. The number of positive wells will allow 
calculating protein quantification in the whole 
sample.
The Simoa platform is highly sensitive, allows 
fast single-molecule diagnostics and requires only 
100 μl reaction volume [30]. Additionally, the assay 
is fully automated and is already implemented in 
different fields such as inflammation, oncology 
and neurology [28–30]. Although it has not yet 
been implemented in HIV-1 diagnostics, Simoa 
offers great potential in quantifying HIV-1 p24 
capsid protein. In a study by Wilson et al., 24 
blood samples from individuals with early HIV-1 
infection were assayed for p24 antigen detec-
tion [29]. Although most samples were negative 
by conventional p24 immunoassay, they were all 
detected using Simoa assay, demonstrating its 
superior sensitivity. The LOD was estimated to be 
2.5 fg/ml, which corresponds approximately to 60 
RNA copies/ml. The assay was as sensitive as PCR 
for detecting HIV-1 in early infection and may 
thus offer a new opportunity for HIV-1 screen-
ing during acute infection and therapy follow-
up. Although this assay needs some specialized 
equipment, it is simple, low cost and holds great 
potential for measuring the true size of the LR.
Conclusion & future perspective
Herein we reviewed the complexity of measur-
ing the HIV-1 LR, whose exact nature and size 
is still not precisely determined. Currently, LR 
lies somewhere between 1 and 1000 latently 
infected cells per million CD4+ T cells, and 
estimated to be more likely around 10–100. 
Current methods fail to measure accurately the 
LR, even if TILDA, iCARED and Simoa are 
probably closer to reality. Additional effort is 
required to develop low-cost assays that will cap-
ture only intact and thus replication -competent 
viral sequences with high accuracy, sensitivity 
and specificity. Moreover, these assays should 
be optimized for routine use in clinical settings.
Nowadays, a proper understanding of the in 
vivo correlation between LR size and time to 
rebound or cure remains crucial. It is becoming 
increasingly urgent to identify reliable biomark-
ers able to quantify the in vivo reservoir over 
time and predict time to viral rebound. Recent 
promising studies by Kiselinova et al. [31] and 
Williams et al. [32] suggest that the pool of HIV-1 
DNA (total or integrated) reflects the size of the 
replication-competent virus in patients receiv-
ing ART and also better predict disease pro-
gression and time for viremia to rebound upon 
treatment interruption than plasma viral load. 
Hence, PCR-based assays quantifying HIV-1 
DNA likely represent the best surrogate marker 
to date to evaluate the size of the LR and thus 
to assess the efficiency of cure strategies. This 
would be key to identify HIV-1 infected indi-
viduals able to safely interrupt ART in future 
clinical HIV-1 eradication trials. The clinical 
benefit of novel assays such as iCARED, TILDA 
and Simoa has not yet been investigated in vivo 
but may contribute to the determination of LR 
size in the future.
Finally, although the simplest way to measure 
the LR remains blood sampling, this does not 
reflect anatomical sites harboring stably integrated 
proviruses [2,15]. It remains thus essential in the 
coming years to adequately define if all potential 
reservoirs must be analyzed and quantified, and 
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EXECUTIVE SUMMARY
What is the HIV-1 reservoir?
 ●  Two main sources are thought to contribute to the viral reservoir: the persistence of productive infected cells in 
lymphoid tissues and anatomical sites that are inaccessible to antiretroviral therapy (ART); and the persistence of 
latently infected cells that are able to produce viral particles upon stimulation.
 ●  The reservoir is established early during infection and remains difficult to apprehend.
 ●  Current methods only quantify the latent reservoir (LR).
Culture-based assays to measure the LR
 ●  Culture-based assays aim at measuring the LR by assessing the number of cells that carry replication-competent 
viruses.
 ●  Quantitative viral outgrowth assay (QVOA) is the current gold standard to measure the LR.
 ●  Improvements of QVOA include MOLT4/CCR5 viral outgrowth assay and murine viral outgrowth assay.
 ●  Culture-based assays tend to underestimate the bona fide size of the LR as they are depending on the ex vivo ability 
of cells to be stimulated and produce infectious viral particles. Therefore, these measurements may lead to premature 
discontinuation of ART, where patients may experience viremia rebounds.
PCR-based assays to measure the LR
 ●  PCR-based assays are commonly used methods that detect all intracellular proviruses regardless of their ability to be 
replication competent or not, and overestimating consequently the total LR.
 ●  Quantitative PCR (qPCR) is used to assess HIV-1 proviruses. HIV-1 DNA measured by qPCR is correlated to integrated 
HIV-1 DNA and to viral rebound in patients on suppressive ART.
 ●  Improvements of qPCR include droplet digital PCR.
 ●  PCR-based assays tend to overestimate the bona fide size of the LR as they quantify both competent and defective 
viral sequences. Therefore, these measurements may represent the current best option to help deciding the legitimacy 
of a safe ART cessation.
The next-generation assays
 ●  Next-generation assays, such as tat/rev-induced limiting dilution assay, inducible cell-associated RNA expression in 
dilution and single molecule arrays, offer an alternative to better estimate the LR, based on viral RNA or protein.
 ●  These assays have not yet been investigated in vivo but may contribute to the determination of LR size in the future.
how to be confident that these reservoirs have 
reached a threshold sufficient for remission or 
cure. Certainly, size matters.
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